C4 Therapeutics (CCCC) Income from Continuing Operations (2019 - 2026)
C4 Therapeutics' quarterly Income from Continuing Operations came in at 25129000.0 in Q1 2026, up 4.53% year-on-year from 24039452.59 in Q1 2025, and down 23.39% quarter-over-quarter from 20365000.0 in Q4 2025.
C4 Therapeutics has reported Income from Continuing Operations for 8 years, with the latest figure at 25129000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 4.53% year-over-year to 25129000.0; the trailing twelve-month figure through Mar 2026 stood at 103680000.0 (changed 0.39% YoY), and the FY2025 full-year result was 104994000.0, changed 0.31% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 25129000.0, down from 20365000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 17716000.0 in Q2 2024, with the low at 37185000.0 in Q4 2022.
- Average Income from Continuing Operations over 5 years is 29144411.76, with a median of 28361000.0 recorded in 2024.
- Year-over-year, Income from Continuing Operations tumbled 137.48% in 2022 and surged 50.68% in 2024.
- Tracing CCCC's Income from Continuing Operations over 5 years: stood at 37185000.0 in 2022, then rose by 6.53% to 34757000.0 in 2023, then rose by 0.53% to 34573000.0 in 2024, then jumped by 41.1% to 20365000.0 in 2025, then dropped by 23.39% to 25129000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 25129000.0 (Q1 2026), 20365000.0 (Q4 2025), and 32166000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | C4 Therapeutics | 561.03 Mn | 325.36 Mn | - | -25.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.13 Mn |
| Dec 31, 2025 | -20.37 Mn |
| Sep 30, 2025 | -32.17 Mn |
| Jun 30, 2025 | -26.02 Mn |
| Mar 31, 2025 | -26.32 Mn |
| Dec 31, 2024 | -34.57 Mn |
| Sep 30, 2024 | -24.67 Mn |
| Jun 30, 2024 | -17.72 Mn |
| Mar 31, 2024 | -28.36 Mn |
| Dec 31, 2023 | -34.76 Mn |
| Sep 30, 2023 | -27.04 Mn |
| Jun 30, 2023 | -35.92 Mn |
| Mar 31, 2023 | -34.78 Mn |
| Dec 31, 2022 | -37.19 Mn |
| Sep 30, 2022 | -31.96 Mn |
| Jun 30, 2022 | -26.88 Mn |
| Mar 31, 2022 | -31.62 Mn |
| Dec 31, 2021 | -15.66 Mn |
| Sep 30, 2021 | -24.68 Mn |
| Jun 30, 2021 | -22.58 Mn |
| Mar 31, 2021 | -20.97 Mn |
| Dec 31, 2020 | -21.80 Mn |
| Sep 30, 2020 | -21.84 Mn |
| Jun 30, 2020 | -10.79 Mn |
| Mar 31, 2020 | -11.91 Mn |
| Dec 31, 2019 | -10.02 Mn |
| Sep 30, 2019 | -10.09 Mn |